Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Haemonetics (HAE) Equity Average (2016 - 2025)

Haemonetics has reported Equity Average over the past 16 years, most recently at $880.3 million for Q4 2025.

  • Quarterly results put Equity Average at $880.3 million for Q4 2025, down 1.4% from a year ago — trailing twelve months through Dec 2025 was $880.3 million (down 1.4% YoY), and the annual figure for FY2025 was $890.4 million, changed 0.16%.
  • Equity Average for Q4 2025 was $880.3 million at Haemonetics, up from $865.7 million in the prior quarter.
  • Over the last five years, Equity Average for HAE hit a ceiling of $951.6 million in Q1 2024 and a floor of $687.8 million in Q4 2021.
  • Median Equity Average over the past 5 years was $846.4 million (2023), compared with a mean of $820.1 million.
  • Biggest five-year swings in Equity Average: rose 24.89% in 2021 and later decreased 9.23% in 2025.
  • Haemonetics' Equity Average stood at $687.8 million in 2021, then increased by 9.4% to $752.5 million in 2022, then grew by 22.06% to $918.5 million in 2023, then fell by 2.79% to $892.9 million in 2024, then fell by 1.4% to $880.3 million in 2025.
  • The last three reported values for Equity Average were $880.3 million (Q4 2025), $865.7 million (Q3 2025), and $851.6 million (Q2 2025) per Business Quant data.